A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale.
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
About 10 minutes. No charge unless your clinician approves.
Individualized means medically chosen.
There is a difference between wanting a gentler version of a medication and having a clinical reason for an individualized formulation. This product is built around the second idea.
The compounded preparation combines semaglutide with vitamin B12 in one prescription. Semaglutide activates the GLP-1 receptor, affecting appetite signaling, gastric emptying, and glucose-dependent insulin response. Vitamin B12 is required for normal red blood cell formation, neurologic function, and cellular metabolism.
Each component has established biology. The combination itself deserves more discipline. Evidence from FDA-approved semaglutide finished drug products does not establish that adding B12 improves semaglutide efficacy or tolerability, or that this compounded preparation will reproduce the results of an FDA-approved finished drug product.
That boundary is what makes the individualized case meaningful. Your clinician reviews prior tolerability, medical history, medications, goals, and the specific rationale for compounding before deciding whether this formulation belongs in your care. It is not a lower-dose option selected at checkout.
The microdose has one primary job: create a lower-scale starting path for a clinician-selected patient. B12 is a visible formulation difference, and a lower dose remains a real prescription decision, not a wellness sample.
Read the evidence →For the case where individualization has a clinical reason.
The Sensitive Responder
Prior medication tolerability is part of your medical history, not a personality trait. You want the formulation decision made with that history in view rather than assuming the standard path fits everyone.
The Individualized Case
A clinician has a specific reason to consider a compounded combination rather than a standard finished product. The reason comes from the case, not from a preference for “microdosing.”
The Holding Pattern
During care, a provider may determine that a reduced-dose phase fits the patient's current clinical picture. The dose is set by the provider and is not an entry point selected at signup.
Compounded semaglutide is not an FDA-approved drug product. This formulation is prescribed where a provider determines a lower dose is clinically indicated. It is not selectable at checkout.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Hypersensitivity to cobalt or vitamin B12
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Semaglutide + B12 Microdose, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Clinician review of your Assessment, medications, history, goals, and prior tolerability
- Individual prescribing decision on whether the compounded semaglutide and B12 combination is appropriate
- Preparation by a licensed 503A pharmacy if approved
- Treatment changes remain clinician-directed rather than self-selected
- Ongoing follow-up connected to the broader metabolic plan
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Metabolic.
Semaglutide
A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model. (Contains semaglutide.)
Tirzepatide
Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up. (Contains tirzepatide.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
What the research shows
GLP-1 is a gut hormone released after meals and cleared very rapidly.
The detail
Glucagon-like peptide-1 is a 30-amino-acid peptide hormone produced in intestinal epithelial endocrine L-cells by differential processing of proglucagon, released in response to meal intake, and inactivated extremely rapidly by the enzyme dipeptidyl peptidase-4.1
It drives glucose-dependent insulin secretion, slows gastric emptying and promotes satiety.
The detail
As an incretin it is secreted within minutes of nutrient ingestion, and incretin-receptor activation on pancreatic islet beta-cells leads to glucose-dependent insulin secretion, while glucagon-like peptide-1 additionally exerts glucoregulatory action through slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion and promotes satiety.2
Semaglutide is a GLP-1 analogue with an elimination half-life of about one week.
The detail
Semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor, and FDA labeling describes the resulting mechanism as glucose-dependent stimulation of insulin secretion and lowering of glucagon secretion with a minor delay in early postprandial gastric emptying, and identifies albumin binding as the principal mechanism of protraction behind an elimination half-life of approximately one week.3
Labeling describes GLP-1 as an appetite regulator acting in the brain.
The detail
FDA labeling further describes glucagon-like peptide-1 as a physiological regulator of appetite and caloric intake, states that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation, and reports that animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.4
B12 is labeled as essential to growth, cell reproduction, hematopoiesis and myelin synthesis.
The detail
Vitamin B12 is described in cyanocobalamin injection labeling as essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis, and cyanocobalamin is quantitatively and rapidly absorbed from intramuscular and subcutaneous injection sites, then transported by the binding proteins transcobalamin I and II to the tissues.5
What it does not show
A compounded preparation is not an FDA-approved drug product.
The detail
A compounded preparation is not an FDA-approved drug product: FDA states that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.6
Everything above is mechanism, not outcome.
The detail
No trial results are cited here. Everything above is drawn from the clinical pharmacology section of FDA labeling, which describes how the molecule acts. This block deliberately stops there rather than reproducing the separate clinical studies section in which trial results for FDA-approved finished drug products are reported, because a described pathway is not a measured outcome.3
B12 labeling describes no effect on body weight, appetite or energy expenditure.
The detail
Cyanocobalamin injection labeling confines its indications to vitamin B12 deficiency due to malabsorption and to use in the vitamin B12 absorption test, and it describes no effect of vitamin B12 on body weight, appetite or energy expenditure.5
Adding B12 to semaglutide has no established effect; FDA has not evaluated the combination.
FDA advises compounded drugs only when no approved drug fits, and flags equivalence claims.
The detail
FDA advises that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug, and identifies a claim that a compounded drug is the same as an FDA-approved drug as a warning sign for consumers.7
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA-approved semaglutide prescribing information, section 12.1…DailyMed
- FDA-approved cyanocobalamin injection, USP prescribing information…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.FDA
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
- Sensitivity to cobalt or vitamin B12
Serious risks
- Pancreatitis
- Gallbladder disease
- Acute kidney injury following the fluid loss that severe vomiting or diarrhea can cause
- Serious hypersensitivity reactions have been reported after parenteral administration of injected vitamin B12
Commonly reported
- Mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal pain
- Alongside that, soreness or redness where you inject
Pancreatitis history and pregnancy plans are reviewed before anything is prescribed. Injected vitamin B12 carries its own labeled cautions. Those risks are described for the individual components rather than for this compounded combination, which has no safety database of its own. Your clinician is the one who decides whether it belongs in your case.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
A provider may determine that a lower-dose path fits a specific clinical picture after reviewing your history, response, tolerability, and goals. Dose selection is a prescribing decision and is not made at checkout.
Your Assessment is reviewed by a licensed provider, typically completed in under 24 hours. If approved, the pharmacy compounds and ships your prescription. Fulfillment timing can vary with pharmacy volume, and your care team keeps you updated.
Gastrointestinal effects seen with semaglutide can include nausea, constipation, and reflux. Mild soreness at the injection site can occur. Your provider selects the dose from your clinical picture, manages anything that surfaces, and adjusts your plan. Persistent or severe symptoms should always go to your care team promptly.